New diabetes drug HDM1005 faces off against mazdutide in major trial
NCT ID NCT07417306
First seen Feb 21, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tests a new medicine called HDM1005 against an existing drug, mazdutide, in about 900 adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone or with another diabetes pill. The goal is to see which drug works better at lowering blood sugar levels over 40 weeks. Participants will receive one of two doses of HDM1005 or mazdutide, all given as injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.